Lassa fever vaccine

Sibbald, Barbara
August 2005
CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p243
Academic Journal
Reports on the development of a vaccine that fully protects nonhuman primates from experimental infection with lethal doses of Lassa virus by a team of U.S. and Canadian scientists. Purpose of the research; Use of a vesicular stomatitis virus in the research; Disease caused by the Lassa virus.


Related Articles

  • A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. Safronetz, David; Mire, Chad; Rosenke, Kyle; Feldmann, Friederike; Haddock, Elaine; Geisbert, Thomas; Feldmann, Heinz // PLoS Neglected Tropical Diseases;Apr2015, Vol. 9 Issue 4, p1 

    Background: Lassa virus (LASV) is endemic in several West African countries and is the etiological agent of Lassa fever. Despite the high annual incidence and significant morbidity and mortality rates, currently there are no approved vaccines to prevent infection or disease in humans....

  • Serological Assays Based on Recombinant Viral Proteins for the Diagnosis of Arenavirus Hemorrhagic Fevers. Fukushi, Shuetsu; Tani, Hideki; Yoshikawa, Tomoki; Saijo, Masayuki; Morikawa, Shigeru // Viruses (1999-4915);Oct2012, Vol. 4 Issue 10, p2097 

    The family Arenaviridae, genus Arenavirus, consists of two phylogenetically independent groups: Old World (OW) and New World (NW) complexes. The Lassa and Lujo viruses in the OW complex and the Guanarito, Junin, Machupo, Sabia, and Chapare viruses in the NW complex cause viral hemorrhagic fever...

  • Inhibition of Lassa Virus Glycoprotein Cleavage and Multicycle Replication by Site 1 Protease-Adapted α1- Antitrypsin Variants. Maisa, Anna; Ströher, Ute; Klenk, Hans-Dieter; Garten, Wolfgang; Strecker, Thomas // PLoS Neglected Tropical Diseases;Jun2009, Vol. 3 Issue 6, p1 

    Background: Proteolytic processing of the Lassa virus envelope glycoprotein precursor GP-C by the host proprotein convertase site 1 protease (S1P) is a prerequisite for the incorporation of the subunits GP-1 and GP-2 into viral particles and, hence, essential for infectivity and virus spread....

  • Single Immunization With a Monovalent Vesicular Stomatitis Virus-Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus. Falzarano, Darryl; Feldmann, Friederike; Grolla, Allen; Leung, Anders; Ebihara, Hideki; Strong, James E.; Marzi, Andrea; Takada, Ayato; Jones, Shane; Gren, Jason; Geisbert, Joan; Jones, Steven M.; Geisbert, Thomas W.; Feldmann, Heinz // Journal of Infectious Diseases;2011 Supplement 3, Vol. 204, pS1082 

    The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform...

  • Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates. Mire, Chad E.; Geisbert, Joan B.; Agans, Krystle N.; Satterfield, Benjamin A.; Versteeg, Krista M.; Fritz, Elizabeth A.; Feldmann, Heinz; Hensley, Lisa E.; Geisbert, Thomas W. // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus...

  • Lassa Virus Genome. Lukashevich, Igor S.; Salvato, Maria S. // Current Genomics;Oct2006, Vol. 7 Issue 6, p351 

    Lassa virus (LASV), the most dangerous human pathogen among the Arenaviridae, belongs to a complex of genetically related virus strains responsible for the deaths of thousands of people in West Africa each year. The virus has a bi-segmented (L and S) single-stranded RNA genome. Each segment...

  • Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus. Mire, Chad E.; Geisbert, Joan B.; Marzi, Andrea; Agans, Krystle N.; Feldmann, Heinz; Geisbert, Thomas W. // PLoS Neglected Tropical Diseases;Dec2013, Vol. 7 Issue 12, p1 

    Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for human use. Recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which encode an EBOV glycoprotein in place of...

  • Vaccination of Mice with Replication-Defective Human Immunodeficiency Virus Induces Cellular and Humoral Immunity and Protects against Vaccinia Virus-gag Challenge. Baliga, Christopher S.; van Maanen, Marc; Chastain, Michael; Sutton, Richard E. // Molecular Therapy;Sep2006, Vol. 14 Issue 3, p432 

    Here we describe as a potential vaccine candidate a replication-defective HIV that encodes multiple viral genes in addition to a cassette that includes both truncated cyclin T1 and an autofluorescent protein. After confirming functionality of the cyclin T1, we immunized mice intramuscularly once...

  • Imported Lassa Fever in Germany: Molecular Characterization of a New Lassa Virus Strain. Gunther, Stephan; Emmerich, Petra; Laue, Thomas; Kuhle, Olaf; Asper, Marcel; Jung, Annegret; Grewing, Thomas; Meulen, Jan ter; Schmitz, Herbert // Emerging Infectious Diseases;Sep/Oct2000, Vol. 6 Issue 5, p466 

    We describe the isolation and characterization of a new Lassa virus strain imported into Germany by a traveler who had visited Ghana, Cote D'lvoire, and Burkina Faso. This strain, designated "AV," originated from a region in West Africa where Lassa fever has not been reported. Viral S RNA...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics